Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial

RECOMMENDED

Interstitial Lung Disease

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

★ 2 Recommended by Dr Martin Frey, Faculty Member

Ann Rheum Dis.

Seibold JR, Maher TM, Highland KB, Assassi S, Azuma A, Hummers LK, Costabel U, von Wangenheim U, Kohlbrenner V, Gahlemann M, Alves M, Distler O, SENSCIS trial investigators

doi: 10.1136/annrheumdis-2020-217331.

RECOMMENDED

Interstitial Lung Disease

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease

N Engl J Med.

Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM, SENSCIS Trial Investigators.

doi: 10.1056/NEJMoa1903076.

RECOMMENDED

Interstitial Lung Disease

Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial

★ 1 Recommended by Dr Martin Frey, Faculty Member

Respir Med

Inoue Y, Suda T, Kitamura H, Okamoto M, Azuma A, Inase N, Kuwana M, Makino S, Nishioka Y, Ogura T, Takizawa A, Ugai H, Stowasser S, Schlenker-Herceg R, Takeuchi T

doi: 10.1016/j.rmed.2021.106574

RECOMMENDED

Interstitial Lung DiseasePulmonary Fibrosis

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med.

Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M, INBUILD trial investigators.

doi: 10.1016/S2213-2600(20)30036-9.

PHARMA NEWS

Interstitial Lung Disease

Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD¹

doi: 10.1056/NEJMoa1903076

RECOMMENDED

Interstitial Lung DiseasePneumonia

[New developments in systemic sclerosis-associated interstitial lung disease]

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Rev Med Suisse

Humair G, Daccord C, Beigelman-Aubry C, Lazor R

CoughInterstitial Lung Disease

Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases

Respirology.

Cheng JZ, Wilcox PG, Glaspole I, Corte TJ, Murphy D, Hague CJ, Ryerson CJ

doi: 10.1111/resp.13084.

SPECIAL REPORT

Interstitial Lung Disease

OFEV^® extended indication offers new hope for patients with SSc-ILD

RECOMMENDED

Interstitial Lung DiseasePulmonary Fibrosis

Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Respir Med

Schmid U, Weber B, Magnusson MO, Freiwald M

doi: 10.1016/j.rmed.2021.106369

Related content

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease

Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD1

[New developments in systemic sclerosis-associated interstitial lung disease]

Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases

OFEV® extended indication offers new hope for patients with SSc-ILD

Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease

Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD¹

OFEV^® extended indication offers new hope for patients with SSc-ILD